13,60 €
ERTRÄGE
Das Unternehmen zahlt regelmäßig eine Dividende von 0,39 € pro Aktie mit einer Rendite von 2,58% – moderat und attraktiv. Die Ausschüttungsquote von 52,26% ist hoch – ein großer Teil des Gewinns wird an Aktionäre ausgeschüttet. Die Dividende wächst minimal um 0,13% – das Unternehmen priorisiert Stabilität über Expansion.
0,39 $
Jährliche Dividende
2,58 %
Rendite
0,13 %
Dividenden-Wachstum
52,26 %
Ausschüttungsquote
UNTERNEHMEN
6,4 Mrd. $
Umsatz
1,45 %
Umsatz-Wachstum
644,5 Mio. $
Nettogewinn
-
12,3 %
ROE -
10,1 %
ROS -
6,0 %
ROA -
26,2 %
GPM
1,4 Mrd. $
Operativer Cashflow
5,2 Mrd. $
Eigenkapital
17.349
Mitarbeiter
-
368.452,2 $
Umsatz / MA -
37.150,0 $
Gewinn / MA
KGV
20,23 $KBV
2,52 $KCV
15,14 $KUV
2,06 $EV/EBITDA
10,75 $EV/EBIT
16,86 $EV/FCF
20,71 $EV/Umsatz
2,82 $EnterpriseValue
18,0 Mrd. $Eigenkapitalrendite
12,31 %Umsatzrendite
10,08 %EBIT-Marge
16,71 %EBITDA-Marge
26,23 %Kapitalumschlag
0,60 $Gesamtkapitalrendite
6,00 %Eigenkapitalquote
0,49 $Fremdkapitalquote
0,51 $Verschuldungsgrad
1,05 $Dyn. Verschuldungsgrad
4,04 $Sachinvestitionsquote
-0,36 $Anlagendeckungsgrad 1
1,24 $Anlagendeckungsgrad 2
0,73 $Liquidität 1. Grades
0,36 $Liquidität 2. Grades
1,17 $Liquidität 3. Grades
2,33 $Dividende pro Aktie
0,39 $Dividendenrendite
2,58 %Ausschüttungsquote
52,26 %Buchwert pro Aktie
6,04 $Cashflow pro Aktie
1,57 $Stand: 30.06.2026 TTM
Fakten
-
Sitz
Großbritannien
-
Hauptsitz
Watford
-
Börsengang
21.04.2009
-
Ausstehende Aktien
866,84 Mio.
-
Mitarbeiter
17,35 Tsd.
-
Währung
GBP
-
Sektor
Gesundheitswesen
-
Industrie
Medical - Devices
-
Börse
OTC
-
Ticker
SNNUF
-
Webseite
Aktie
Unternehmensinfos
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products...
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.